Quick Answer
CG Oncology, Inc. reported Cash and Equivalents of $32.49 million for fiscal year 2025.
CG Oncology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $32.49M | -87.4% |
| 2024 | $257.07M | +3009.9% |
| 2023 | $8.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $45.15M | +4.0% | +208.7% |
| June 30, 2025 | $14.62M | -41.9% | -64.7% |
| March 31, 2025 | $41.47M | -46.5% | -83.9% |
| December 31, 2024 | $257.07M | +3009.9% | +492.2% |
| September 30, 2024 | $43.41M | — | +72.6% |
| June 30, 2024 | $25.16M | — | -67.5% |
| March 31, 2024 | $77.47M | — | +837.2% |
| December 31, 2023 | $8.27M | — | — |
- CG Oncology, Inc. showed a decrease of -87.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, CG Oncology, Inc.’s cash and equivalents has grown by 293.1% (from $8.27 million to $32.49 million).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: